scholarly journals The C-reactive Protein/Albumin Ratio Is an independent Prognostic Factor for Overall Survival in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy

2016 ◽  
Vol 7 (14) ◽  
pp. 2005-2011 ◽  
Author(s):  
Chang-Juan Tao ◽  
Yuan-Yuan Chen ◽  
Feng Jiang ◽  
Xing-Lai Feng ◽  
Qi-Feng Jin ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Nasopharyngeal Carcinoma ◽  
Intensity Modulated Radiotherapy ◽  
Independent Prognostic Factor ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Intensity Modulated

Modified-Nutrition Index is a Significant Prognostic Factor for the Overall Survival of the Nasopharyngeal Carcinoma Patients who Undergo Intensity-modulated Radiotherapy

2017 ◽  
Vol 69 (7) ◽  
pp. 1011-1018 ◽  
Author(s):  
Jin-Sheng Hong ◽  
Yang-Jing-Ling Hua ◽  
Li Su ◽  
Hai-Rong Zhang ◽  
Wen-Long Lv ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Nasopharyngeal Carcinoma ◽  
Intensity Modulated Radiotherapy ◽  
Significant Prognostic Factor ◽  
Intensity Modulated

scholarly journals Elevated High-Sensitivity C-Reactive Protein Levels Predict Decreased Survival for Nasopharyngeal Carcinoma Patients in the Intensity-Modulated Radiotherapy Era

PLoS ONE ◽  
2015 ◽  
Vol 10 (4) ◽  
pp. e0122965 ◽  
Author(s):  
Lin Quan Tang ◽  
Dong Peng Hu ◽  
Qiu Yan Chen ◽  
Lu Zhang ◽  
Xiao Ping Lai ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Intensity Modulated Radiotherapy ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Protein Levels ◽  
Reactive Protein ◽  
Intensity Modulated

scholarly journals The Ratio of C-Reactive Protein/Albumin is a Novel Inflammatory Predictor of Overall Survival in Cisplatin-Based Treated Patients with Metastatic Nasopharyngeal Carcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-9 ◽  
Author(s):  
Peng Sun ◽  
Cui Chen ◽  
Yi Xia ◽  
Xiwen Bi ◽  
Panpan Liu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factor ◽  
Nasopharyngeal Carcinoma ◽  
Prognostic Value ◽  
C Reactive Protein ◽  
Platelet To Lymphocyte Ratio ◽  
Reactive Protein ◽  
Risk Of Mortality ◽  
Metastatic Nasopharyngeal Carcinoma ◽  
Ebv Dna

The C-reactive protein/albumin (CRP/Alb) ratio has been recently identified as a prognostic factor in various cancers, whereas its role remains unclear in metastatic nasopharyngeal carcinoma (NPC). The current study retrospectively analyzed 148 patients with metastatic NPC who underwent cisplatin-based chemotherapy and further evaluated the prognostic value of the CRP/Alb ratio and its association with clinical characteristics in these patients. The optimal cut-off value was 0.189 for the CRP/Alb ratio. The high CRP/Alb ratio was significantly associated with elevated NLR, platelet-to-lymphocyte ratio (PLR), and EBV-DNA levels and decreased haemoglobin level (all p<0.05). The results of multivariate analysis showed that the CRP/Alb ratio was an independent prognostic factor of overall survival. Patients with a high CRP/Alb ratio (≥0.189) had a 1.867 times (p=0.024, 95% CI=1.085–3.210) greater risk of mortality compared with those with a low CRP/Alb ratio (<0.189). In addition, combining the CRP/Alb ratio with GPS could accurately discriminate the prognosis of our patients. Our results suggested that the CRP/Alb ratio is a feasible and inexpensive tool for predicting survival outcomes and is a valuable coadjutant for the GPS to further identify differences in survivals of patients with metastatic NPC.

scholarly journals C-Reactive Protein/Albumin Ratio (CAR) as a Prognostic Factor in Patients with Non-Metastatic Nasopharyngeal Carcinoma

2016 ◽  
Vol 7 (15) ◽  
pp. 2360-2366 ◽  
Author(s):  
ShaSha He ◽  
Yan Wang ◽  
HaiYang Chen ◽  
Lin Yang ◽  
ShaoBo Liang ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Nasopharyngeal Carcinoma ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Metastatic Nasopharyngeal Carcinoma

C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma – A data from multi-institutional study in Japan

2019 ◽  
Vol 37 (11) ◽  
pp. 812.e1-812.e8 ◽  
Author(s):  
Takuya Tsujino ◽  
Kazumasa Komura ◽  
Takeshi Hashimoto ◽  
Ryu Muraoka ◽  
Naoya Satake ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein

scholarly journals Induction Chemotherapy Combined With Intensity-Modulated Radiotherapy for 129 Nasopharyngeal Carcinoma Patients With Synchronous Metastases: A Retrospective Study

2021 ◽  
Vol 11 ◽  
Author(s):  
Mengshan Ni ◽  
Lijun Geng ◽  
Fangfang Kong ◽  
Chengrun Du ◽  
Ruiping Zhai ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Nasopharyngeal Carcinoma ◽  
Induction Chemotherapy ◽  
Survival Rates ◽  
Intensity Modulated Radiotherapy ◽  
Initial Diagnosis ◽  
Intensity Modulated ◽  
Synchronous Metastases ◽  
Pre Treatment

ObjectiveTo analyze the therapeutic effect and prognostic factors of nasopharyngeal carcinoma (NPC) patients with distant metastases at initial diagnosis receiving induction chemotherapy with intensity-modulated radiotherapy (IMRT).MethodsA total of 129 patients who underwent platinum-based induction chemotherapy followed by definitive IMRT with or without concurrent or adjuvant chemotherapy for newly diagnosed distant metastatic NPC in our center between March 2008 and November 2018 were retrospectively analyzed. 41 patients underwent local therapy for metastatic sites. Kaplan-Meier method was used to estimate survival rates, Log-rank test and Cox proportional hazards model were used to figure out independent prognostic factors of overall survival (OS).ResultsA total of 66 patients had been dead (median follow-up time, 51.5 months). The median overall survival (OS) time was 54.2 months (range, 7-136 months), and the 1-year, 2-year, 3-year, 5-year overall survival rates were 88.0%,71.0%,58.0%, and 47.0%. Multivariate analysis found that the factors correlated with poor overall survival were pre-treatment serum lactate dehydrogenase (SLDH) &gt;180U/L, chemotherapy cycles&lt;4, and M1 stage subdivision (M1b, single hepatic metastasis and/or multiple metastases excluding the liver; and M1c, multiple hepatic metastases). The 5-year OS rates for M1a, M1b and M1c were 62.6%,40.4% and 0%, respectively.ConclusionPlatinum-containing induction chemotherapy combined with IMRT seemed to be advantageous to prolong survival for some NPC patients with synchronous metastases at initial diagnosis. The independent factors to prognosticate OS were pre-treatment SLDH, number of chemotherapy cycles, and M1 subcategories. Prospective clinical trials are needed to confirm the result.

scholarly journals Is maximum primary tumor diameter still a prognostic factor in patients with nasopharyngeal carcinoma treated using intensity-modulated radiotherapy?

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Yong Chen ◽  
Xue-Feng Hu ◽  
Yan Wang ◽  
Hai-Yang Chen ◽  
Lin Yang ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Nasopharyngeal Carcinoma ◽  
Primary Tumor ◽  
Intensity Modulated Radiotherapy ◽  
Tumor Diameter ◽  
Intensity Modulated

C-reactive protein as an independent prognostic factor for metastatic gastric cancer.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 110-110 ◽  
Author(s):  
Mika Kitagawa ◽  
Takaya Shimura ◽  
Tomonori Yamada ◽  
Keisuke Itoh ◽  
Chihiro Hasegawa ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Progression Free Survival ◽  
Metastatic Gastric Cancer ◽  
Independent Prognostic Factor ◽  
C Reactive Protein ◽  
Antitumor Effects ◽  
Eligibility Criteria ◽  
Reactive Protein ◽  
Serum Crp

110 Background: S-1 plus cisplatin has been recognized as the standard chemotherapy for metastatic gastric cancer (MGC). Inflammation is considered to be a critical component of tumor progression. C-reactive protein (CRP) has been associated with the development of many cancers, but the significance of CRP remains unclear for MGC. The present study assessed the relationship between serum levels CRP and antitumor effects in MGC. Methods: Among 109 MGC patients who received S-1 plus cisplatin as first-line chemotherapy from January 2006 to December 2011 in 3 Japanese institutions, we retrospectively identified 70 patients who fulfilled eligibility criteria of this study. Patients were categorized into 2 groups depending on serum CRP level before chemotherapy: 43 patients with CRP <1.0 mg/dl (CRP <1.0 group) and 27 patients with CRP ≥1.0 mg/dl (CRP ≥1.0 group). Results: Median overall survival was significantly shorter in the CRP ≥1.0 group than in the CRP <1.0 group [267 days (95% CI, 208 to 326) versus 416 days (95% CI, 325 to 507); p = 0.0007]. Moreover, progression-free survival (PFS) was significantly shorter in the CRP ≥1.0 group than in the CRP <1.0 group (median PFS 126 days [95% CI, 63 to 189) versus 188 days (95% CI, 159 to 217); p = 0.0050]. Meanwhile, response rate was determined in 58 patients with target lesions. No significant differences were noted between the CRP <1.0 group and the CRP ≥1.0 group (10/33, 30.3% versus 7/25, 28.0%; p = 0.663). In a multivariate analysis, serum CRP level before chemotherapy was an only independent prognostic factor for MGC (hazard ratio 3.09 (95% CI, 1.46 to 6.54); p = 0.003). Conclusions: Serum CRP level before chemotherapy might be an independent and potential prognostic factor for MGC. Stringent follow-up during chemotherapy is expected for patients with MGC and a high CRP level.

Evaluation of serial measurements of C-reactive protein: Albumin ratio in patients with clear cell renal cell carcinoma.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 695-695
Author(s):  
Dattatraya H Patil ◽  
Ella N Anastasiades ◽  
Mersiha Torlak ◽  
Aaron Lay ◽  
Mehrdad Alemozaffar ◽  
...  
Keyword(s):  
Overall Survival ◽  
Risk Stratification ◽  
Repeated Measures ◽  
Clear Cell ◽  
Surgical Stress ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
T Stage ◽  
Clear Cell Rcc

695 Background: Sequential measurements of prognostic markers is an important protocol for accurate prediction of clinical outcomes in clear cell RCC. We propose that change in value of C-Reactive Protein to albumin ratio before and after surgery would be a good prognostic indicator for assessment of overall survival and risk stratification in clear cell RCC. Methods: Patients that underwent nephrectomy for clear cell RCC between 2007 and 2016 were followed up with CRP-Albumin measurements for 3 post-op visits (1, 3, 6 months). All measurements between post-op day 1 to 21 were excluded from analysis owing to possible confounding effect due to surgical stress. We assessed if change in CRP-Albumin ratio from pre-operative level is associated with any patient and tumor characteristics by fitting linear regression generalized estimating equations models to account for correlation in repeated measures. Average change in level for each post-op visit was used to stratify for an eventual end of follow-up outcome. Results: 302 clear cell RCC patients were treated with nephrectomy with mean age at surgery was 59.9±11 years, and mean BMI of 30.1± 6.6. 103 patients had at least 2 time-points available after surgery. Table 1 depicts mean CRP-Albumin ratio with 95% CI for each visit stratified with vital status. A linear GEE model fitted for baseline factors affecting change in ratio , identified t-stage, Fuhrman nuclear grade, gender, and BMI as significantly associated (p < 0.05). Conclusions: Serial measurement of CRP/Albumin ratio is useful factor for personalized risk-stratification for prognosticating overall survival as well as recurrence in patients with clear cell RCC. Significant effect of T-stage, tumor grade, and BMI depicts close relationship of CA-ratio and established risk predictors. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document